Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- Conditions
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT02018861
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT01929941
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 121
- Registration Number
- NCT01905813
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 55
- Registration Number
- NCT01858883
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT01822756
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT01685255
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 44
- Registration Number
- NCT01641107
- Locations
- 🇮🇹
Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni", Ascoli, Italy
🇮🇹Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy
🇮🇹Azienda Ospedaliera - Papa Giovanni XXIII, Bergamo, Italy
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT01634087
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 87
- Registration Number
- NCT01633372
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
- Conditions
- Interventions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01632904